AUG 22, 2018 9:43 PM PDT

New Clinical Assay Useful For Urothelial Cancer

WRITTEN BY: Nouran Amin

U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in urothelial carcinoma. The assay is the only approved companion diagnostic to help identify patients with urothelial carcinoma for treatment with KEYTRUDA, which is a monoclonal anti-PD1 therapy manufactured by the pharmaceutical company known Merck for the first-line treatment option of cancer.

Specifically, KEYTRUDA is approved for cancer patients experiencing locally advanced or metastatic urothelial carcinoma and who are not eligible for cisplatin-containing chemotherapy. Additionally, their tumors must express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined through an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy.

The pharmDx assay referred to as ‘PD-L1 IHC 22C3’ follows previous FDA-approved assay for non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and cervical cancer. "Anti-PD-1 therapies are a promising treatment class for many cancer types, and early PD-L1 testing can provide critical information to physicians managing urothelial carcinoma patients," explains Sam Raha, the president of Agilent's Diagnostics and Genomics Group. "By expanding the use of PD-L1 IHC 22C3 pharmDx, Agilent strives to address the unmet need for treatment options in patients who are ineligible for cisplatin-containing chemotherapy. Through these efforts, we maintain our commitment to bringing companion diagnostics to the market in support of groundbreaking immuno-oncology therapeutics."

The 5th most common cancer in the United States, urothelial carcinoma holds an estimated incidence of 81,000 new diagnoses in just 2018. For 30 years, cancer-related morality has not approved for patients with advanced/metastatic urothelial carcinoma with a five-year survival rate of approximately 15%. Additionally, the age along with disease-associated comorbidities affect patient eligibility for standard treatments such as cisplatin-containing chemotherapy. Patients that cannot be administered cisplatin-containing chemotherapy, will have an unmet need for effective therapy.

Source: Agilent

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 10, 2020
Cancer
A New Prognostic Biomarker for Paclitaxel Sensitivity in Breast Cancer
AUG 10, 2020
A New Prognostic Biomarker for Paclitaxel Sensitivity in Breast Cancer
Breast cancer is one of the deadliest cancers globally. It has been studied extensively with plenty of treatments availa ...
AUG 20, 2020
Clinical & Molecular DX
Machines Learn the Difference Between Autism and Schizophrenia
AUG 20, 2020
Machines Learn the Difference Between Autism and Schizophrenia
 
SEP 01, 2020
Clinical & Molecular DX
Scalp Implants Monitor Epileptic Seizures
SEP 01, 2020
Scalp Implants Monitor Epileptic Seizures
Neuroscientists have developed devices that, when implanted under the scalp of individuals living with epilepsy, can mon ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
OCT 13, 2020
Clinical & Molecular DX
Test for Diabetes Checks If the Liver Is Responding
OCT 13, 2020
Test for Diabetes Checks If the Liver Is Responding
Glucagon is a hormone that prevents blood glucose levels from dropping too low by stimulating the liver to convert store ...
OCT 22, 2020
Cardiology
Using Liposomes to Deliver Repair Packages to the Heart
OCT 22, 2020
Using Liposomes to Deliver Repair Packages to the Heart
The secret to any successful drug is not just its ability to treat a disease but its ability to target the disease exclu ...
Loading Comments...